Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, Davis
With
CareDx
This is a prospective, randomized open-labeled study of kidney transplant recipients who have previously received two doses of mRNA COVID-19 vaccine (either BNT162b2, Pfizer-BioNTech or mRNA-1273, Moderna) and who are eligible to receive a 3rd dose of mRNA vaccine.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant is willing and able to give informed consent for participation in the study
First or repeat kidney transplant recipient
Negative or low positive antibody titer on SARS-CoV-2 antibody assay
On a mycophenolate or azathioprine based immunosuppressive regimen
\> 6 months post-transplant
You may not be if
Pregnancy
Contraindication to SARS-CoV-2 vaccination (severe allergic reactions or anaphylaxis)
Clareo Health | Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
